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Background
Ovarian cancer is one of the commonest cancers in
women and the leading cause of death from gynaecologi-
cal malignancy in the western world. About 205,000 cases
of ovarian cancer are diagnosed worldwide each year [1].
It accounts for 3% of female cancers in Ireland with over
350 new cases each year [2]. Marked heterogeneity is a
hallmark of the disease, not only in tumor histotype and
grade but also in response to chemotherapy and overall
prognosis [3]. Over 90% of cases arise from the surface
epithelium. Serous adenocarcinomas are the commonest
and account for 40%–50% of malignant neoplasms [4].
The majority of ovarian cancers present in advanced stages
(III or IV) and are treated by surgery and systemic chemo-
therapy, most frequently carboplatin and paclitaxel. Con-
ventional chemotherapy is still unsatisfactory as it ignores
aspects of tumor biology. Despite an initial 70–80%
response rate, current therapy is frequently followed by
recurrence which is often resistant to chemotherapy, as
demonstrated by the 5–20% long-term survivors [5].
Understanding the biological mechanisms underlying
recurrence of ovarian cancer and addressing chemoresist-
ance is of the utmost importance for improving treatment
and outcome of the disease. Previous studies using single
gene biomarkers to predict tumor response have been
inconclusive. Patterns of gene expression for recurrence
are likely to involve multiple gene pathways and integra-
tion of these pathways.
High throughput discovery tools such as DNA microar-
rays have enabled the study of gene expression profiles of
large numbers of cancer samples. Several groups have suc-
cessfully applied expression array technology to the
molecular classification of ovarian cancers [6,7], confirm-
ing a process of differentiation in the progression of ovar-
ian cancer [8] and others have attempted to predict
outcome and chemotherapeutic response [9,10]. Previous
studies in our laboratory focused on assays and markers to
predict response to chemotherapy [11,12].
While numerous studies have characterized primary ovar-
ian cancers, less information is available regarding expres-
sion patterns of recurrent ovarian cancers. The aim of this
study was to determine whether primary and recurrent
ovarian tumors could be distinguished based on their
gene expression profiles, by using gene expression arrays
and to identify potential biomarkers of recurrence.
Results
Gene expression profiling distinguishes primary and 
recurrent ovarian cancers
A flow chart of our study design is shown in Figure 1. To
identify potentially important mediators of recurrence in
the most frequent histological pattern of ovarian cancer,
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we performed cDNA microarray experiments on a homog-
enous set of primary and recurrent serous papillary ovar-
ian tumors (cohort 1). Gene expression profiling revealed
a total of 907 genes as differentially expressed between
primary and recurrent samples at p < 0.01. Using the more
stringent false discovery rate (FDR 0.1), this list was nar-
rowed down to 182 genes. Included in this FDR list (with
the exception of CLDN16, which was the top differentially
expressed gene in the p value list), were BTC,  S100B,
IL27RA,  CSRP2,  ARFRP1,  PVRL2,  WASF1,  STARD10,
LASS4, LGALS3BP, CASK, IFNGR1, PGM2L1, USF2, PERP,
ESM, CHORDC1, RNPC1, MGAT4B and CACNA1D which
were selected for validation. Table 1 displays the fold
changes observed for these genes, the corresponding
probe identification and the p values.
To address whether recurrence follows similar patterns
and to avoid individual genetic variation, we profiled
paired samples from the same patient (cohort 2). A total
of 586 genes were differentially expressed between pri-
mary and recurrent at p < 0.05 and this was reduced to 75
genes at p < 0.01. Genes with a fold change >4, upregu-
lated in recurrent compared to primary tumors included:
Septin 6,  ZNF218,  S100A8,  MMP9,  FOXF1  and  ILIR2
(Table 2).
Hierarchical heat maps, presented in Figures 2a and 2b,
for both cohorts, demonstrated distinct gene expression
patterns between primary and recurrent ovarian cancers.
Notably, upregulated genes in the recurrent compared to
primary tumors in cohort 1 and 2 segregated in the same
gene families. Included among these genes are S100B and
S100A8 belonging to the S100 family of calcium binding
Table 1: List of gene targets selected for TaqMan® validation in cohort 1
Gene Symbol Probe ID P value Array fold change Expression in 
recurrent vs primary
Assay ID
CLDN16 163630 0.0068 9 Upregulated Hs00198134_m1
S100B 114188 0.0001 6.12 Upregulated Hs00389217_m1
CACNAID 127127 0.00012 3.9 Upregulated Hs00167753_m1
BTC 112710 0.0006 2.67 Upregulated Hs00156140_m1
IL27RA 145754 0.0005 1.82 Upregulated Hs00175472_m1
CHORDC1 183675 0.0002 1.359 Upregulated Hs00854389_m1
LASS4 155606 1.78E-05 9.02 Downregulated Hs00226114_m1
STARD10 115998 4.26E-05 6.03 Downregulated Hs00246405_m1
CSRP2 137165 0.0003 5.7 Downregulated Hs00426717_m1
RNPC1 215065 0.0003 4.87 Downregulated Hs00246405_m1
ARFRP1 118657 0.0003 4.85 Downregulated Hs00182389_m1
ESM1 174810 0.005 4.68 Downregulated Hs00199831_m1
CASK 143978 0.00035 4.42 Downregulated Hs00177620_m1
WASF1 118398 0.0001 4.32 Downregulated Hs00187514_m1
PVRL2 128369 0.0002 4.23 Downregulated Hs00161054_m1
MGAT4B 186405 0.0002 4.13 Downregulated Hs00365001_m1
LGALS3BP 185853 9.49E-05 4.12 Downregulated Hs00174774_m1
PERP 141176 0.0004 3.52 Downregulated Hs00751717_m1
PGM2L1 138177 0.0005 3.04 Downregulated Hs00328100_m1
IFNGR1 190183 0.0003 2.57 Downregulated Hs00166223_m1
USF2 144617 0.0005 1.94 Downregulated Hs00231528_m1
Flow chart of our study design Figure 1
Flow chart of our study design. 2 cohorts were used in this 
study: In the first one, we selected a homogeneous series of 
primary and recurrent serous papillary adenocarcinomas 
from different patients(Between patient cohort). The second 
cohort consisted of 3 paired ovarian cancers (primary and 
recurrent samples coming from the same patient) but of dif-
ferent histology (Within patient cohort). Selected genes iden-
tified from microarray experiments were validated for both 
cohorts and a subset of these genes (n = 12) were validated 
in an independent set (test set) of 13 serous papillary adeno-
carcinomas using TaqMan® PCR.
Within patients
(n=6)
Between patients
(n=10)
Independent set
(n=13)
selected targets
(12 genes)
Microarray
qRT-PCR
21 genes 10 genes
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cytoplasmic proteins, TJP3 and CLDN16 belonging to the
family of tight junction proteins, BTC and NRG2 belong-
ing to the family of EGFR ligands, and interleukin recep-
tors IL1R2 and IL27RA (Figure 3).
Validation of gene expression by qRT-PCR
Using TaqMan®  PCR we validated dysregulated genes
against different interrogation sets in order to select those
likely to represent markers of recurrence (Figure 4). A list
of the genes chosen for validation together with their
molecular function and biological processes is shown in
additional file 1. Correlation was carried out using Spear-
man correlation co-efficient. The fold changes in the
arrays were plotted against relative quantitation from the
TaqMan®  analyses of recurrent versus primary tumors.
High concordance was revealed between TaqMan® and
microarray experiments in cohort 1 (r = 0.874, p < 0.01)
(Figure 5) and cohort 2 (r = 0.845, p < 0.05) (Figure 6).
IL1R2 and ZNF218 identified in cohort 2 as upregulated
in recurrent, when validated in samples from cohort 1,
gave the best distinction with fold changes of 2.81 and
2.94 respectively (Figure 7). No significant difference was
observed between recurrent and primary samples for the
Hierarchical cluster heatmaps demonstrating distinct patterns of gene expression between primary and recurrent ovarian  tumors Figure 2
Hierarchical cluster heatmaps demonstrating distinct patterns of gene expression between primary and recurrent ovarian 
tumors. (a) Heatmap of the ovarian tumors in cohort 1 based on the FDR0.1 list with the primary clustering on the left and the 
recurrent samples on the right. Vertical bars represent the samples and the horizontal bars represent the genes. Green bars 
reflect downregulated genes and red bars upregulated genes. (b) Heat map discriminating recurrent (left) and primary (right) 
ovarian tumours in cohort 2 based on the p0.01 list. P, primary tumours; R, recurrent tumors.
ab
Table 2: List of gene targets selected for TaqMan® Validation in cohort 2
Gene Symbol Probe ID P value Array fold change Expression in 
recurrent vs primary
Assay ID
S100A8 196494 0.034 11.6 Upregulated Hs00374263_m1
ZNF218 217273 0.002 6.06 Upregulated Hs00542836_m1
MMP9 112640 0.0169 4.975 Upregulated Hs00234579_m1
IL1R2 186009 0.038 4.46 Upregulated Hs00174759_m1
SEPTIN6 122775 0.019 4.16 Upregulated Hs00248408_m1
NRG2 170215 0.013 3.6 Upregulated Hs00171706_m1
SPDEF 155169 0.005 2.87 Upregulated Hs00171942_m1
TJP3 182089 0.013 2.7 Upregulated Hs00274276_m1
FGF2 113042 0.03 2.7 Upregulated Hs00266645_m1
FOXF1 145754 0.0015 6.58 Downregulated Hs00230962_m1Molecular Cancer 2008, 7:8 http://www.molecular-cancer.com/content/7/1/8
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remaining 13 which is in accordance with the array
results.
Consecutively independent validation of a subset of the
above genes (n = 12) from both cohorts was carried out in
our test set of primary and recurrent serous papillary ade-
nocarcinomas (n = 13) using TaqMan® PCR to identify if
these targets were possible markers of recurrence for
serous papillary adenocarcinomas (Figure 8). BTC  and
FGF2 provided the best distinction between recurrent and
primary tumors with fold changes of 2.8 and 2.71 respec-
tively. Adding 2 recurrent samples of different histologies
to the previously homogeneous histological sample
cohort conferred no statistical significance for any of the
validated genes (fold changes < 2). These were subse-
quently excluded from the analysis to preserve homoge-
neity in the test set.
The results confirm the utility of the derived set of markers
as potential markers of recurrence. Recurrence is rather
multifactorial as indicated by non identification of a sin-
gle biochemical pathway to relate the above targets using
the ingenuity program [13].
Discussion
This investigation demonstrates a distinct pattern of gene
expression between primary and recurrent ovarian carci-
nomas in vivo and represents an effort to discover poten-
tially important mediators of recurrence. It also addresses
whether mechanisms of gene dysregulation in primary
versus recurrent paired tumors are unique to those pairs.
In order to address chemoresistance and minimise param-
eters introducing variations, well characterized tumors of
the commonest histological subtype (serous papillary
adenocarcinoma) were selected in cohort 1. In cohort 2,
we used paired samples with identical genetic background
(from the same patients). Such samples are valuable since
second-look laparotomy in Europe is a rather uncommon
practice in the treatment of ovarian cancer. To our knowl-
edge, this dual approach of profiling primary and recur-
rent ovarian cancers in vivo has never been previously
performed.
Unsupervised hierarchical clustering of the samples in
both cohorts unambiguously separated primary and
recurrent tumors. The substantial number of gene expres-
sion differences between the two groups, in particular
cohort 2, reflects progression of the tumours from a pri-
mary to a relapsed state, but is also consistent with the
hypothesis that tumor cells surviving chemotherapeutic
treatment alter their gene expression allowing them to
withstand the selective pressure of the drugs used. In fact,
the "log kill" effect of cytotoxic chemotherapy signifi-
cantly reduces tumor cells that are sensitive to the admin-
istered therapy [14]. Hence, one is inclined to think that
recurrent tumors are enriched with resistant clones and
likely to display molecular signatures more associated
with acquired chemoresistance. Acquired resistance is
likely to reflect changes in gene regulation rather than
mutation-dependent clone selection [15], especially in
solid tumors which have relatively low doubling rates.
Nonetheless, genes upregulated in recurrent compared to
primary advanced ovarian tumors could be invoked as
"recurrent metastasis virulent genes" that provide a selec-
tive advantage in recurrent sites but not in primary tumor-
igenicity [16].
Validation of targets was satisfactory as indicated by
Spearman coefficients. Some variation may be due to dif-
ferences in sensitivity between the two techniques, proba-
bly because of the number of absent cells made during
normalisation of the microarray data or the asymmetry in
the number of samples used in both cohorts.
Gene families involved in the molecular regulation of recurrence in ovarian cancer Figure 3
Gene families involved in the molecular regulation of recurrence in ovarian cancer. Some of the upregulated genes in recurrent 
compared to primary ovarian carcinomas that we validated in cohort 2 belong in the same gene families with some of the 
upregulated genes validated in cohort 1. Upregulation of tight junction proteins and EGFR ligands, development of a cytokine 
response via interleukin receptors and intracellular signaling via calcium binding S100 proteins seem to contribute to the 
"recurrent" signature and possibly have a role in drug resistance.
Cohort 1
Cohort 2
EGFR Ligands S1OO ILRx
S100A8            TJP3                 NRG2                 IL1R2
S100B           CLDN16               BTC                  IL27RA
between
patients
within
patients
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We identified and validated genes upregulated in the
recurrent tumors, which may be the signature expression
pattern of drug resistant cancers (Table 1). Some of the
genes identified in the two cohorts belong to the same
gene families corroborating the importance of several dis-
tinct gene families in the molecular regulation of ovarian
cancer recurrence. Since all patients in both cohorts were
treated with platinum based therapy and some of the
identified genes are thought to be correlated to the mode
of action of chemotherapeutic agents as discussed below,
it is interesting to speculate that some of the mechanisms
involved in recurrence are specific to the drugs used.
Whether the genes represent etiologic causes of drug
resistance or treatment failure remains to be further
answered.S100B was the most differentially upregulated
gene in recurrent serous tumors (FDR 0.1). It constitutes a
calcium binding cytoplasmic protein, involved in intracel-
lular signaling. Historically used in the clinical manage-
ment of malignant melanomas, it was found to be a
negative regulator of p53 [17]. If elevated S100B levels
cause downregulation of p53, apoptotic pathways are not
induced resulting in uncontrolled tumor growth or resist-
ant phenotypes [18]. A recent proteomic study identified
TaqMan® PCR validation of microarray experiments in  cohort 2 Figure 6
TaqMan® PCR validation of microarray experiments in 
cohort 2. A similar concordance was observed as in cohort 
1.
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TaqMan® PCR validation of target genes identified in both  training and test sets Figure 4
TaqMan® PCR validation of target genes identified in both 
training and test sets. Gene selection for TaqMan® validation 
was based on the most differentially expressed genes from 
the p and FDR value list with a fold change > 4 but also 
included genes that had a 2–4 fold change and also some 
genes involved in the most differentially expressed pathways. 
Priority was given to selection of genes upregulated in recur-
rent compared to primary samples, which might provide 
"recurrence" signatures in ovarian cancer. Upregulated genes 
validated in both cohorts were alternatively interrogated 
(external validation) and further advanced for validation in 
the test set. Independent validation on a test set refers to 
completely distinct samples of serous histology that were not 
previously employed in marker development (n = number of 
gene targets selected for validation).
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Target selection
TaqMan® PCR validation of microarray experiments in  cohort 1 Figure 5
TaqMan® PCR validation of microarray experiments in 
cohort 1. The fold changes in the arrays were plotted against 
the relative quantitation from TaqMan® in recurrent vs pri-
mary tumours. The TaqMan® values are displayed in blue and 
the array results in red. Spearman correlation r showed high 
concordance between the 2 experiments.
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a putative S100 protein to be upregulated in cisplatin
resistant cell lines [19]. Other members of the S100 fam-
ily, including S100A8, identified in cohort 2, are overex-
pressed in common cancers. S100B is also involved in the
assembly and disassembly of microtubules[20] and there-
fore might interfere with the mechanism of action of tax-
anes.
CLDN16 was the most upregulated gene in the recurrent
serous tumors (p < 0.01) in cohort 1. It belongs to the
family of claudins, tight junction (TJs) – associated pro-
teins endowed with well-characterized roles in individual
viability, epithelial differentiation and tumor growth
probably by stabilizing tumor cell connection. A link
between cisplatin exposure and cytoskeletal alterations
has been reported [21]. Notably, CLDN16 has been char-
acterized as a novel human ovarian cancer-specific tran-
script using serial analysis of gene expression data [22].
Other members of the family, CLDN3 and CLDN4 are fre-
quently overexpressed in ovarian cancer. They have also
been described to function as receptors for Clostridium
Perfringens Enterotoxin [23], a finding that might open
novel treatment approaches in ovarian cancer. Expression
levels of CLDN10 are associated with recurrence of pri-
mary hepatocellular carcinoma [24]. A proteomic study
identified CLDN4 as overexpressed in cisplatin resistance
cell lines [19]. TJP3, another discriminatory gene identi-
fied in cohort 2, anchors to the cytoplasmic tail of clau-
dins [25]. No studies on the relationship between TJs and
chemotherapy response have been carried out. The func-
tional role of CLDN16  and  TJP3  in carcinogenesis is
unknown. As loss of cell-cell contact has been noted to
induce apoptosis [26], one would hypothesise that
increased contact through tight junctions as a result of
upregulation of these component proteins may favor
tumor survival. Transmembrane proteins are also more
likely to remodel the tumor microenvironment to favor
drug resistance [27].
Of particular interest are putative markers among the
coexpressed genes ILIR2 and ZNF218 that we validated in
cohort 2 and they provided the best discrimination
between primary and recurrent serous neoplasms in
cohort 1. The role of cytokines and their receptors is well
established in the epithelial cancer microenvironment
[28] with IL8 and IL6 known to be involved ovarian can-
cer pathogenesis [29]. A novel regimen of immunomodu-
latory cytokines and carboplatin show promising results
on completion of a phase II clinical trial, in recurrent ovar-
ian cancer [30]. IL-1, a proinflammatory cytokine, is
required for tumor invasiveness and angiogenesis in a
variety of malignant lesions [31] and particularly in met-
astatic human tumor specimens [32]. Targeting IL1R2
may be an appropriate therapeutic strategy for inhibiting
tumor angiogenesis. IL1R2 may provide an insight into
the biology of recurrent ovarian tumors, suggesting an ini-
tial immune response to the relapsing neoplasm and may
secondly represent a surrogate marker of recurrence in
ovarian cancer.
ZNF 218 encodes for a newly described zinc finger protein
located on chromosome 20q13.2 and has never been pre-
viously reported in ovarian cancer. Frequent amplification
Independent TaqMan® PCR validation of a set of selected  genes from both cohorts in a test set of serous papillary ade- nocarcinomas of varying grade and stage Figure 8
Independent TaqMan® PCR validation of a set of selected 
genes from both cohorts in a test set of serous papillary ade-
nocarcinomas of varying grade and stage. BTC and FGF2 pro-
vided the best distinction between recurrent and primary 
tumours with fold changes of 2.8 and 2.71 respectively.
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of DNA at 20q has been demonstrated by comparative
genomic hybridization in ovarian cancer [33] and is asso-
ciated with poor prognosis [34]. Given that amplification
appears to be the predominant mechanism leading to
overexpression of genes, ZNF 218 emerges as a strong can-
didate oncogene related to ovarian cancer [35].
External validation using independent sets of samples is a
critical step in view of the potential for false-discovery
using microarrays. In this regard, a test set of 13 serous
papillary ovarian adenocarcinomas (primary and recur-
rent) of various stages and grades, given the same initial
chemotherapy treatment, was used for relative quantita-
tion of 12 targets upregulated in recurrent versus primary
tumors. An elevated mRNA expression (FC > 2) was
observed for 2 out of 12 genes, namely BTC and FGF2,
which bind to Epidermal Growth Factor Receptor (EGFR
or ErbB1) and Fibroblast Growth Factor Receptor (FGFR)
respectively. These genes gave the best distinction between
primary and recurrent tumors in our test set of serous
tumors. The inclusion of two tumors (n = 2) of nonserous
histologies (i.e. yolk sac and clear cell) in the previously
homogenous test set conferred no statistical significance
for any of the validated genes (FC < 2), suggesting that var-
ious histological types may have variable chemosensitivi-
ties. Since EGFR and FGFR stimulate a similar repertoire of
intracellular signaling pathways [36], this certain pattern
of expression evident in the recurrent serous ovarian can-
cers deserves special consideration.
Despite the well established significance of EGFR in the
progression of ovarian cancer [37], the role of EGF ligands
in ovarian cancer is still poorly understood. Overexpres-
sion of EGFR is found in up to 75% of ovarian cancers and
is associated with chemoresistance and poor prognosis
[38]. Our study suggests that overproduction of ligands
(BTC and NRG2), rather than overproduction of receptors
could be the predominant mechanism that the ErbB path-
way uses to generate cancer cell proliferation signals.
Combined targeting of ErbB receptors and their ligands
produces a synergistic antitumor effect [39] because of
their non-overlapping functions.
BTC binding to EGFR initiates significant signal transduc-
tion pathways, such as MAPK and PI-3-kinase-Akt (PI3K/
Akt) [40] in a metalloprotease dependent manner
[41,42]. The PI3K/Akt pathway promotes cell survival and
has been identified as a potential contributor to drug
resistance [43]. MMP-9 co-upregulation was also observed
in our study, which is in agreement with the finding that
MMP-9  (and  MMP-14) mRNA levels are selectively
increased in response to EGFR activity in ovarian tumor
cells [44]. Metalloproteases have also been described in a
novel drug-resistant phenomenon [45]. EGFR ligands and
matrix metalloproteases constitute a vascular-remodeling
program that facilitates pathological angiogenesis in
mammary tumors [46].
FGF ligands are mitogenic growth factors, generally
known to act in a local manner. A recent study on the rep-
ertoire of mutated human cancer genes, based on the fam-
ily of protein kinases, identified the FGF signaling
pathway to confer growth advantage by the highest
enrichment for kinases containing "driver" mutations
[47]. FGF2 has been described in prostate cancer [48] and
implicated in cancer invasion and metastasis, probably
through upregulation of MMP9  [49], which was also
upregulated in our study, as mentioned above. FGF2 crit-
ically modulates mesenchymal-to-epithelial transition,
which is now widely accepted to contribute to carcinoma
invasiveness [50]. These findings would explain the
acquired metastatic capacity or recurrence pattern of
advanced epithelial ovarian cancers, which are mesotheli-
ally derived and suggest a role for FGF2 as an epithelial
marker in strategies to block epithelialization of metas-
tases.
Conclusion
Collectively, our data propose an integrative model for
recurrence in ovarian cancer, in which tumor cells during
relapse produce adhesion molecules to mediate attach-
ment, cytokines and inflammatory mediators to stimulate
survival and a variety of growth factors bound to their cog-
nate receptors to fully proliferate in order to confront and
modulate their immediate environment, which they must
eventually overtake (Figure 9).
To date, the histological type of the ovarian cancer is not
used as a factor to determine chemotherapy management.
As the best strategy for second-line chemotherapy has not
yet been defined, the proposed panel of genes could
reduce at least in individual patients, unnecessary chemo-
therapy treatment and toxicity or alternatively could be
readily used for early detection of disease recurrence.
Clearly, a definite role for the candidate targets will be
provided by functionally investigating the mechanisms
involved in the development of recurrence and drug
resistance. These types of analyses may lead to novel
approaches for the development of therapy aimed at
reversing or decreasing drug resistance or alternatively
optimization of the already available standard drugs [51].
A synchronous targeting of co-amplified genes may in the
future offer better treatment for recurrent ovarian cancer.
Materials and methods
Patients and tissue samples
The study consisted of 2 cohorts: cohort 1 comprised 5
primary serous papillary adenocarcinomas, grade 3, FIGO
stage III and 5 recurrent serous papillary adenocarcinomas
of the same grade. The mean age in years for patients inMolecular Cancer 2008, 7:8 http://www.molecular-cancer.com/content/7/1/8
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the primary and the recurrent group in cohort 1 was 62.6
(range 48–84) and 52.4 (range 43–68). The recurrent
group consisted of patients for which primary surgery was
performed prior to the commencement of the study. In
cohort 2, 3 paired ovarian cancers were used (primary and
recurrent coming from the same patient), but of different
histology, namely papillary serous, mixed mullerian and
clear cell carcinomas. The mean age in years for patients in
cohort 2 was 52 (range 39–74) for the primary and 53.3
(range 43–74) for the recurrent.
To further validate identified gene targets in cohorts 1 and
2, an independent set (test set) of serous papillary ovarian
adenocarcinomas were interrogated. This additional
cohort comprised of 13 serous papillary ovarian adeno-
carcinomas, 10 primary and 3 recurrent cases. An addi-
tional two patients with different histological subtypes of
recurrent ovarian cancer (one patient with well differenti-
ated clear cell carcinoma and one patient with dedifferen-
tiated germ cell carcinoma) were also included in the test
set.
All tumors were staged according to the International Fed-
eration of Gynaecology and Obstetrics standards (FIGO).
Patients were optimally debulked (residual disease of <1
cm in greatest diameter), had received no neoadjuvant
treatment before surgery and they were all treated post
operatively with paclitaxel and platinum. The two addi-
tional recurrent patients in the test set were optimally
debulked, one received postoperative carboplatin/paclit-
axel and the other bleomycin/etoposide/platinum.
All samples were removed as part of patient treatment for
ovarian cancer at St James's Hospital, Dublin, Ireland. The
study had approval of the hospital ethics committee and
informed consent was obtained from each patient by the
research team prior to surgery.
Specimens were snap frozen on collection within 1 hour
of surgery and stored at -80°C. After tissue processing in a
cryostat at -20°C, frozen sections were cut and mounted
on slides. The slides were stained with H&E and examined
by a pathologist to ensure >70% presence of tumor cells.
cDNA Arrays
Samples were placed in liquid nitrogen, ground thor-
oughly with a mortar and pestle and homogenized in RLT
buffer (Qiagen Ltd, UK). Total RNA was extracted using
the Qiagen RNAeasy (Hilden, Germany) RNA Mini Kit
and on-column RNase-free DNase digestion was per-
formed according to the manufacturer's instructions. RNA
quantity and quality was determined using Nanodrop
spectrophotometer (Nanodrop Tehnologies) and the Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Waldbronn,
Germany).
Gene expression profiles were examined using the
Applied Biosystems (ABI) (Foster City, CA, USA) Human
An integrative model for recurrence in ovarian cancer Figure 9
An integrative model for recurrence in ovarian cancer. Schematic representation of putative genes and gene families involved in 
the recurrence of ovarian carcinomas. According to our current working concept, tumour cells during relapse produce adhe-
sion molecules to mediate attachment and invasion via co-overexpression of matrix metalloproteinases, cytokines and inflam-
matory mediators to stimulate survival and a variety of growth factors bound to their cognate receptors to fully proliferate in 
order to confront and modulate their immediate environment, which they must eventually overtake.
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Genome Survey Microarrays V2.0 system. These arrays
contain 32,878 oligonucleotide probes (60 base pairs
long) and target a complete annotated and fully curated
set of 29,098 human genes from the public and Celera
databases. Double stranded cDNA was prepared from 2
micrograms of total RNA using an oligo dT priming
approach followed by in vitro transcription and labelling
to generate Digoxigenin (DIG) labelled cRNA (ABI
Chemiluminescent RT-IVT Labelling Kit) according to the
manufacturer's protocol.
Each microarray was first pre-hybridized at 55°C for 1 hr
in hybridisation buffer with blocking reagent. 10 µg of
labelled cRNA targets were randomly fragmented by incu-
bating with fragmentation buffer at 60°C for 30 min,
mixed with internal control target (ICT, 24-mer oligo
labelled with LIZ fluorescent dye) and then hybridized to
each pre-hybridized microarray at 55°C for 16 hr. Follow-
ing hybridisation, the arrays were washed with hybridisa-
tion wash buffer and chemiluminescence rinse buffer and
stained with anti-DIG alkaline phosphatase, further
enhanced with Chemiluminescence Enhancing Solution
and finally with Chemiluminescence Substrate. Each array
was then scanned on the ABI 1700 Platform for image col-
lection. Technical replicates were performed on a subset
of samples to ensure concordance and only those with
greater than 90% concordance were considered valid.
Bioinformatics
The R statistical package, a free language and environment
was developed to work with the Applied Biosystems
whole genome microarray platform for all the analysis (R
Development Core Team, 2004) [52]. Following quality
control assessments, a two-step algorithm automatically
processed raw image data, including gridding and quanti-
fication so that genes were deemed undetectable if they
had signal-to-noise (S/N) ratio threshold > 3 in 75% of
the samples. Data were normalized with quantile normal-
ization. Paired t and ANOVA tests were performed to gen-
erate p values for statistical differences between the two
groups, with p < 0.05 considered significant. The p values
were further adjusted using more stringent Benjamini-
Hochberg false discovery rate (FDR) at preset levels: 0.01,
0.1. Gene expression profiles were examined based on
fold change, p and FDR values. The R package was used to
visualize hierarchical clustering between differentially
expressed genes. Unsupervised hierarchical clustering was
applied to the data set using the Unweighted Pair Group
Method with Arithmetic Mean (UPGMA) based on Eucli-
dean distance as the similarity measure. Functional classi-
fication of the data and gene ontology was defined by
using the PANTHER (Protein Analysis THrough Evolu-
tionary Relationships) Classification System. A binomial
statistical tool was employed to compare gene lists to a
reference list (i.e. the complete human genome) to deter-
mine over- or under-representation of PANTHER classifi-
cation categories. To further refine the gene lists, it was
investigated if any of these genes were known to interact
biologically. To this end, pathway analysis using the Inge-
nuity Pathways Analysis (IPA) tool was used which is a
web-based software application that enables scientists to
identify the biological mechanisms, pathways and func-
tions most relevant to their experimental datasets or genes
of interest [13].
Expression data from microarray and TaqMan® PCR data
were correlated with nonparametric Spearman's correla-
tion coefficient (r) to avoid distributional assumptions.
Validation of gene expression targets
RNA was initially reverse transcribed using a High Capac-
ity cDNA Archive Kit (Applied Biosystems, CA, USA) and
then was amplified in a 10 µL PCR reaction according to
the manufacturer's recommended protocol and amplifica-
tion steps: denaturation at 95°C, followed by 40 cycles of
denaturation at 95°C for 15 sec and then annealing at
60°C for 1 min. All reactions were carried out on the ABI
Prism 7000 Sequence detection system (Applied Biosys-
tems, Applera UK, Cheshire, UK) using the TaqMan® Uni-
versal PCR master Mix and Assays on demand (Applied
Biosystems). Gene symbols and assay ID's are shown in
Table 1. Relative quantitation was carried out using the
"Delta-Delta Ct" (∆∆Ct) method with 18S ribosomal RNA
as an endogenous control. Transcript quantification was
performed in triplicate for each sample.
The mRNA levels of 31 overall differentially expressed
genes were validated using the assay on Demands™ gene
expression products (Applied Biosystems) real-time quan-
titative RT-PCR assay (TaqMan® Gene expression assay)
with an ABI PRISM 7000 sequence detection system
(Applied Biosystems, CA, USA) (Table 1).
21 genes were selected for our validation in cohort 1. We
selected some of the most differentially expressed genes
(FC > 4) but we also included genes that had a 2–4 fold
change and also some genes involved in the most differ-
entially expressed pathways using the PANTHER bino-
mial statistics tool.
In cohort 2, 10 targets were selected for validation. These
included some of the most differentially expressed genes
from both p value lists but also genes of known biological
significance.
External and independent test set validation
Randomly selected genes identified in cohort 1 as upregu-
lated in recurrent compared to primary samples (n = 5)
were validated against cohort 2 samples. Likewise, ran-
domly selected genes identified in cohort 2 with a specialMolecular Cancer 2008, 7:8 http://www.molecular-cancer.com/content/7/1/8
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emphasis on those again upregulated in recurrent versus
primary (n = 10) were tested against cohort 1 samples.
Validation of 12 upregulated genes in the recurrent sam-
ples from both cohorts was performed in an independent
set of 10 primary and 3 recurrent serous papillary adeno-
carcinomas. An additional 2 recurrent samples of different
histology were included.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Additional material
Acknowledgements
The authors would like to acknowledge N. Gleeson, T. D'Arcy, E. McGuin-
ness and the gynaecology teams in St James's Hospital, Dublin, Ireland, for 
providing us with samples and clinical data used in this study; M. Ring for 
cutting frozen sections; P. Smyth for expert bioinformatic support. We also 
thank the Meath and Emer Casey Foundations and members of the Depart-
ment of Obstetrics and Gynaecology/Histopathology, Trinity College, Dub-
lin, Ireland for helpful discussions.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
2. The National Cancer Registry Ireland   [http://www.ncri.ie]
3. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok
SC, Bandera CA: Ovarian cancer is a heterogeneous disease.
Cancer Genet Cytogenet 2005, 161:170-173.
4. DiSaia PJ, Creasman WT, eds: Epithelial ovarian cancer. Clinical
gynecologic oncology.  St. Louis: Mosby Year Book; 1997:282-350. 
5. Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S:
Advances in treatment of epithelial ovarian cancer.  Nagoya J
Med Sci 2006, 68:19-26.
6. Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, Cheng H: Character-
ization of differentially expressed genes in ovarian cancer by
cDNA microarrays.  Int J Gynecol Cancer 2005, 15:50-57.
7. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn
M, Wang YC, Duran GE, Sikic TL, Caldeira S, et al.: Gene expres-
sion patterns in ovarian carcinomas.  Mol Biol Cell 2003,
14:4376-4386.
8. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila
S: Changes in gene expression during progression of ovarian
carcinoma.  Cancer Genet Cytogenet 2001, 128:1-6.
9. Selvanayagam ZE, Cheung TH, Wei N, Vittal R, Kit Lo KW, Yeo W,
Kita T, Ravatn R, Hung Chung TK, Wong YF, Chin K-V: Prediction
of chemotherapeutic response in ovarian cancer with DNA
microarray expression profiling.  Cancer Genetics and Cytogenetics
2004, 154:63-66.
10. De Smet F, Pochet NL, Engelen K, Van Gorp T, Van Hummelen P,
Marchal K, Amant F, Timmerman D, De Moor BL, Vergote IB: Pre-
dicting the clinical behavior of ovarian cancer from gene
expression profiles.  Int J Gynecol Cancer 2006, 16(Suppl
1):147-151.
11. O'Toole SA, Sheppard BL, McGuinness E, Gleeson NC, Bonnar J:
Serous papillary adenocarcinomas of the ovary display het-
erogeneity in their response to chemotherapy.  International
Journal of Gynecological Cancer 2001, 11:365-371.
12. O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EPJ,
D ' A r c y  T ,  B o n n a r  J :  Potential predictors of chemotherapy
response in ovarian cancer – How do we define chemosensi-
tivity?  Gynecologic Oncology 2007, 104:345-351.
13. Ingenuity Systems   [http://www.ingenuity.com]
14. Skipper HE: Kinetics of mammary tumor cell growth and
implications for therapy.  Cancer 1971, 28:1479-1499.
15. Di Nicolantonio F, Mercer S, Knight L, Gabriel F, Whitehouse P,
Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, et al.: Can-
cer cell adaptation to chemotherapy.  BMC Cancer 2005, 5:78.
16. Nguyen DX, Massague J: Genetic determinants of cancer
metastasis.  Nat Rev Genet 2007, 8:341-352.
17. Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ:
Inhibiting S100B Restores p53 Levels in Primary Malignant
Melanoma Cancer Cells.  J Biol Chem 2004, 279:34071-34077.
18. Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ: Charac-
terization of the Tumor Suppressor Protein p53 as a Protein
Kinase C Substrate and a S100b-Binding Protein.  PNAS 1992,
89:11627-11631.
19. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND,
Hood L, Lin B: Proteins associated with Cisplatin resistance in
ovarian cancer cells identified by quantitative proteomic
technology and integrated with mRNA expression levels.
Mol Cell Proteomics 2006, 5:433-443.
20. Sorci G, Agneletti AL, Donato R: Effects of S100A1 and S100B on
microtubule stability. An in vitro study using triton-cytoskel-
etons from astrocyte and myoblast cell lines.  Neuroscience
2000, 99:773-783.
21. Shen D-W, Liang X-J, Gawinowicz MA, Gottesman MM: Identifica-
tion of Cytoskeletal [14C]Carboplatin-Binding Proteins
Reveals Reduced Expression and Disorganization of Actin
and Filamin in Cisplatin-Resistant Cell Lines.  Mol Pharmacol
2004, 66:789-793.
22. Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR,
Schwartz DR, Shock T, Morin PJ: Remodeling of the extracellular
matrix through overexpression of collagen VI contributes to
cisplatin resistance in ovarian cancer cells.  Cancer Cell 2003,
3:377-386.
23. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y,
Tsukita S: Clostridium perfringens enterotoxin fragment
removes specific claudins from tight junction strands: Evi-
dence for direct involvement of claudins in tight junction
barrier.  J Cell Biol 1999, 147:195-204.
24. Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, So S:
Claudin-10 expression level is associated with recurrence of
primary hepatocellular carcinoma.  Clin Cancer Res 2005,
11:551-556.
25. Gonzalez-Mariscal L, Betanzos A, Avila-Flores A: MAGUK pro-
teins: structure and role in the tight junction.  Seminars in Cell
& Developmental Biology 2000, 11:315-324.
26. Frisch SM, Francis H: Disruption of epithelial cell-matrix inter-
actions induces apoptosis.  J Cell Biol 1994, 124:619-626.
27. Morin PJ: Drug resistance and the microenvironment: nature
and nurture.  Drug Resistance Updates 2003, 6:169-172.
28. Wilson J, Balkwill F: The role of cytokines in the epithelial can-
cer microenvironment.  Seminars in Cancer Biology 2002,
12:113-120.
29. Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, Yao Z: Regulatory
effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian
cancer cells.  Cell Mol Immunol 2005, 2:365-372.
30. Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback
CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, et al.:
Cytokines, GM-CSF and IFNgamma administered by prim-
ing and post-chemotherapy cycling in recurrent ovarian can-
cer patients receiving carboplatin.  J Transl Med 2006, 4:16.
31. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura
Y, Dinarello CA, Apte RN: IL-1 is required for tumor invasive-
ness and angiogenesis.  PNAS 2003, 100:2645-2650.
32. Shao J, Sheng H: Prostaglandin E2 Induces the Expression of IL-
1{alpha} in Colon Cancer Cells.  J Immunol 2007, 178:4097-4103.
Additional file 1
List of selected genes differentially expressed in recurrent versus primary 
tumours in cohorts 1 and 2. The list includes selected genes from both 
cohorts that we chose to validate using TaqMan and gives information 
about their molecular function, biological processes or pathways involved.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-8-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2008, 7:8 http://www.molecular-cancer.com/content/7/1/8
Page 11 of 11
(page number not for citation purposes)
33. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T,
Borg A, Isola JJ: Frequent Amplification of Chromosomal
Region 20q12–q13 in Ovarian Cancer.  Clin Cancer Res 2000,
6:1833-1839.
34. Quinlan KGR, Verger A, Yaswen P, Crossley M: Amplification of
zinc finger gene 217 (ZNF217) and cancer: When good fin-
gers go bad.  Biochimica et Biophysica Acta (BBA) – Reviews on Cancer
2007, 1775:333-340.
35. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang S-
i, Polikoff D, Nonet G, Cochran J, Myambo K, et al.: Positional clon-
ing of ZNF217 and NABC1: Genes amplified at 20q13.2 and
overexpressed in breast carcinoma.  Proceedings of the National
Academy of Sciences 1998, 95:8703-8708.
36. Schlessinger J: Common and Distinct Elements in Cellular Sig-
naling via EGF and FGF Receptors.  Science 2004,
306:1506-1507.
37. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS: Tar-
get-based agents against ErbB receptors and their ligands: a
novel approach to cancer treatment.  Endocr Relat Cancer 2003,
10:1-21.
38. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G,
Greggi S, De Vincenzo R, Mancuso S: Significance of epidermal
growth factor receptor in advanced ovarian cancer.  J Clin
Oncol 1992, 10:529-535.
39. Posters: 6. Epidemiology/Pathology.  Ann Oncol 2002, 13:65-68.
40. Fischer OM, Hart S, Gschwind A, Ullrich A: EGFR signal transac-
tivation in cancer cells.  Biochem Soc Trans 2003, 31:1203-1208.
41. P Oc, Wongkajornsilp A, Rhys-Evans PH, Eccles SA: Signaling path-
ways required for matrix metalloproteinase-9 induction by
betacellulin in head-and-neck squamous carcinoma cells.  Int
J Cancer 2004, 111:174-183.
42. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ull-
rich A: EGF receptor transactivation by G-protein-coupled
receptors requires metalloproteinase cleavage of proHB-
EGF.  Nature 1999, 402:884-888.
43. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW: Apoptosis
defects and chemotherapy resistance: molecular interaction
maps and networks.  Oncogene 2004, 23:2934-2949.
44. Cowden Dahl KD, Zeineldin R, Hudson LG: PEA3 Is Necessary for
Optimal Epidermal Growth Factor Receptor-Stimulated
Matrix Metalloproteinase Expression and Invasion of Ovar-
ian Tumor Cells.  Mol Cancer Res 2007, 5:413-421.
45. Rintoul RC, Sethi T: The role of extracellular matrix in small-
cell lung cancer.  The Lancet Oncology 2001, 2:437-442.
46. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis
RR, Manova-Todorova K, Massague J: Mediators of vascular
remodelling co-opted for sequential steps in lung metastasis.
Nature 2007, 446:765-770.
47. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,
Davies H, Teague J, Butler A, Stevens C, et al.: Patterns of somatic
mutation in human cancer genomes.  Nature 2007,
446:153-158.
48. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED:
Aberrant fibroblast growth factor receptor signaling in blad-
der and other cancers.  Differentiation 2007, 75:831-842.
49. Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S: Basic
Fibroblast Growth Factor Regulates Matrix Metalloprotein-
ases Production and In Vitro Invasiveness in Human Bladder
Cancer Cell Lines.  The Journal of Urology 1997, 157:2351-2355.
50. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams
ED:  Mesenchymal-to-Epithelial Transition Facilitates Blad-
der Cancer Metastasis: Role of Fibroblast Growth Factor
Receptor-2.  Cancer Res 2006, 66:11271-11278.
51. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J,
Cottrill H, Kelley MJ, Petersen R, et al.: Genomic signatures to
guide the use of chemotherapeutics.  Nat Med 2006,
12:1294-1300.
52. BioConductor   [http://www.bioconductor.org]